Investigation of allergic reaction during the treatment of anti-TNF alpha monoclonal antibody in patients with inflammatory bowel diseases
Not Applicable
- Conditions
- inflammatory boewl diseases
- Registration Number
- JPRN-UMIN000010508
- Lead Sponsor
- Saitama Medical Center, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Patients without informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Investigation of biomarker
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie allergic reactions to anti-TNF alpha monoclonal antibodies in inflammatory bowel diseases as studied in JPRN-UMIN000010508?
How does anti-TNF alpha therapy compare to standard-of-care treatments in managing allergic reactions in Crohn's disease and ulcerative colitis patients?
Which biomarkers predict allergic response to anti-TNF alpha monoclonal antibodies in JPRN-UMIN000010508 IBD patients?
What are the safety profiles and management strategies for allergic events in JPRN-UMIN000010508 anti-TNF alpha treatment of IBD?
What are the comparative allergic reaction rates between adalimumab, infliximab, and certolizumab in JPRN-UMIN000010508 IBD patients?